Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy
Opthea Provides Corporate Update
Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials
Opthea Announces Decision to Discontinue Wet AMD Trials
Opthia could owe $1bn to investors amid sozinibercept trial failure
Opthea's Phase 3 Eye Therapy Trial Fails to Meet Primary Endpoint
Opthea Announces COAST Phase 3 Trial Topline Results
Exploring Three High Growth Tech Stocks In Australia
Opthea Limited (OPT): Among the Best Australian Stocks to Buy According to Billionaires
Opthea First Half 2025 Earnings: US$0.11 loss per share (vs US$0.17 loss in 1H 2024)
Opthea Announces Phase 2b Wet AMD Publication
Opthea Reports Half Year Results and Business Updates
Opthea Completes Drug Product PPQ Campaign
Opthea Completes COAST Final Week 52 Patient Visit
Is Opthea Limited (OPT) the Best Long Term ASX Stock to Buy Now?
High Growth Tech Stocks To Explore In February 2025
Opthea to Present at Oppenheimer Healthcare Conference
Opthea Wet AMD Data Featured at Macula Society Meeting
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds?
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
